– Pharmacodynamic profile of GRX-917 indicates potential for anxiolytic activity without the significant sedative side effects associated with benzodiazepines NEW YORK and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that pharmacodynamic data…


Previous articleThe Psychedelic Mind: How Neuroscience Can Help You Navigate Your Inner Landscape
Next articlePsychedelics Weekly – Breaking Convention, Decolonizing the Psychedelic Space, and How Colorado’s Senate Bill 23-290 Will Affect Prop 122